JoVE Logo
Faculty Resource Center

Sign In

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

DOI :

10.3791/59033-v

8:46 min

November 12th, 2019

November 12th, 2019

52,306 Views

1ACEA Biosciences, Inc, 2ProMab Biotechnologies. Inc, 3ACEA Therapeutics

We describe a quantitative real-time in vitro cytolysis assay system to evaluate the potency of chimeric antigen receptor T cells targeting liquid and solid tumor cells. This protocol can be extended to assess other immune effector cells, as well as combination treatments.

Tags

Real time Potency Assay

-- Views

Related Videos

article

Retroviral Transduction of T-cell Receptors in Mouse T-cells

article

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

article

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

article

Real-time Live Imaging of T-cell Signaling Complex Formation

article

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

article

Killer Artificial Antigen Presenting Cells (KaAPC) for Efficient In Vitro Depletion of Human Antigen-specific T Cells

article

Simultaneous Quantification of T-Cell Receptor Excision Circles (TRECs) and K-Deleting Recombination Excision Circles (KRECs) by Real-time PCR

article

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

article

Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain

article

Highly Multiplexed, Super-resolution Imaging of T Cells Using madSTORM

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved